Form 4: Hologic Executive Boosts Stake with RSU Grant

Hologic's President of GYN Surgical, Brandon Schnittker, reported an acquisition of 12,113 restricted stock units and related tax-driven dispositions of common stock.

Summary

• Brandon Schnittker, President of GYN Surgical at Hologic Inc. (HOLX), reported transactions involving the company's common stock.
• On November 7, 2025, 138 shares of common stock were disposed of at $74.1 per share to cover tax obligations related to restricted stock unit (RSU) settlement.
• On November 10, 2025, Schnittker acquired 12,113 restricted stock units (RSUs). These RSUs vest in equal installments on each of the first three anniversaries of the grant date, November 10, 2025, and are settled one-for-one in common stock.
• On November 11, 2025, an additional 289 shares of common stock were disposed of at $74.6 per share for tax obligations connected to RSU settlement.
• Following these transactions, Schnittker's direct beneficial ownership of common stock stands at 17,780 shares.

Sentiment

Score: 7

Explanation: The grant of a significant number of restricted stock units to a key executive is generally viewed positively as it aligns management's long-term interests with shareholder value, despite routine tax-related dispositions.

Positives

• Acquisition of 12,113 restricted stock units (RSUs) by a key executive, indicating continued alignment of management interests with shareholders.
• The increase in beneficial ownership from 5,956 shares (after the first disposition) to 17,780 shares (after all reported transactions) demonstrates a significant increase in the executive's stake in the company.

Negatives

• Dispositions of 138 shares at $74.1 and 289 shares at $74.6 were made to cover tax obligations, which is a routine event and not inherently negative.

Future Outlook

The restricted stock units granted on November 10, 2025, are scheduled to vest in equal installments on the first three anniversaries of that date, indicating future share issuances to the executive.

Industry Context

This filing reflects standard executive compensation practices within the medical technology industry, where restricted stock units are commonly used to align executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive aligns management's long-term interests with shareholder value, potentially fostering sustained performance.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Vesting of the 12,113 restricted stock units in equal installments on November 10, 2026, November 10, 2027, and November 10, 2028.

Key Dates

Recommendation

This Form 4 details routine executive compensation, specifically the grant of restricted stock units and associated tax-related share dispositions. While the increased beneficial ownership by a key executive is a positive signal of alignment, these transactions are standard and do not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals.

Keywords

Hologic, HOLX, Insider Trading, Form 4, Restricted Stock Units, RSU, Executive Compensation, Stock Grant, Beneficial Ownership